With a current price increase of 2.09%, Cipla's stock reflects positive market dynamics and strong investor sentiment.

Widaplik is a single tablet, triple combination therapy for hypertension that is expected to be available in the fourth quarter of 2025. The Food and Drug Administration (FDA) has approved Widaplik ™ ...

The FDA has approved a new pill called Widaplik, which combines three drugs – telmisartan, amlodipine, and indapamide – to treat adults who have high blood pressure.

WIDAPLIK is a combination tablet of telmisartan, an angiotensin II receptor blocker, amlodipine, a dihydropyridine calcium channel blocker and indapamide, a thiazide-like diuretic, available in ...

WIDAPLIK is a proprietary single pill combination of three medicines: telmisartan, amlodipine and indapamide and is available in three doses: a standard dose and two low doses.

George Medicines announces FDA approval of Widaplik™ (telmisartan, amlodipine and indapamide), a new single pill combination treatment for hypertension in adults, including initial treatment.

WIDAPLIK is a combination tablet of telmisartan, an angiotensin II receptor blocker, amlodipine, a dihydropyridine calcium channel blocker and indapamide, a thiazide-like diuretic, available in three ...

The FDA has approved Widaplik (telmisartan, amlodipine and indapamide) for the treatment of hypertension, including as initial treatment, to lower blood pressure.

The Viwoods AI Paper is a great e-ink tablet for students and readers. It’s great for note taking, reading, and sketching at a reasonable price.

Cipla’s shares have surged 6% since saying last week it received final approval from the US Food and Drug Administration for its generic version of Bristol Myers Squibb’s Abraxane, a cancer drug.

The TCL Nxtpaper 11 Plus seamlessly shifts from full color to an ink-like paper display in seconds, posing a serious challenge to both Android tablets and Kindles.